Safety and effectiveness of an acellular pertussis vaccine in subjects with Down's syndrome

Child's Nervous System

Volumn 12, Issue 2, 1996, Pages 100-102

  Li Volti, S ^a   Mattina, T ^a   Mauro, L ^a   Bianca, S ^a   Anfuso, S ^a   Ursino, A ^a   Mollica, F ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Acellular pertussis vaccine; Down's syndrome; Immunization

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; PERTUSSIS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; VACCINATION;

ANTIBODY FORMATION; BORDETELLA PERTUSSIS; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; IMMUNOGLOBULIN G; INFANT; PERTUSSIS VACCINE; SAFETY; TREATMENT OUTCOME; WHOOPING COUGH;

EID: 0030025432     PISSN: 02567040     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00819505     Document Type: Article

References (14)

1. Booy R, Aitken SJM, Taylor S, et al (1992) Immunogenicity of combined diphtheria-tetanus and pertussis vaccine given at 2, 3, and 4 months versus 3, 5 and 9 months of age. Lancet 339:507-510
2. Cherry JD, Brunell PA, Golden GS, Karzan DT (1988) Report of the task force on "pertussis and pertussis immunization 1988". Pediatrics 81:933
3. Gordon MC, Sinha SK (1971) Antibody responses to influenza vaccine in patients with Down's syndrome. Am J Ment Defic 75:391-397
4. Hawkes RA, Boughton CR, Scroeter DR (1978) The antibody response of instituzionalized Down's syndrome patients to seven microbial antigens. Clin Exp Immunol 31:298-303
5. Hollinger Blaine F, Goyal RK, Hersch T, Powell HC, Schulman RJ, Melnick JL (1972) Immune response to hepatitis virus type B in Down's syndrome and other mentally retarded patients. Am J Epidemiol 95:356-362
6. Illingworth R (1981) Toxicity of pertussis vaccine. Br Med J 285:210-211
7. Menkes JH, Kinsbourne M (1990) Workshop on neurologic complications of pertussis and pertussis vaccinations. Neuropediatrics 21:171-175
8. Novo E, Garcia MI, Lavergne J (1993) Non specific immunity in Down syndrome: a study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells. Am J Med Genet 46:384-391
9. Nurmi T, Leinonen M, Haiva WM, Tilikainen A, Konvalainen K (1982) Antibody response to pneumococcal vaccine in patients with trisomy 21 (Down's syndrome). Clin Exp Immunol 48:485-490
10. Podda A, Nencioni L, Marsili I, et al (1991) Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 9:741-745
11. Preston NW (1994) Pertussis vaccination: neither panic nor complacency. Lancet 2:491-492
12. Stewart GT (1979) Toxicity and pertussis vaccine: frequency and possibility of reactions. J Epidemiol Community Health 32:150
13. Thomson RG, Rowlins MD, James OFW, Tyrer SP, Codd A (1989) Prevalence of hepatitis B in mental handicap hospital. Lancet 1:44-45
14. Wahl M, Harmadssan S, Iwarsen S (1983) Immune responses to hepatitis B vaccine in the mentally retarded. J Infect 7 [Suppl 1]:47